ATLANTA — Epilepsy experts are getting a better picture of the long-term safety and efficacy of azetukalner, a novel and potent Kv7 potassium channel opener, in patients with treatment-resistant focal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback